- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07653646
Restrictions on Maternity Ward Visits: Current Situation, Challenges and Recommendations in the Auvergne Rhone-Alpes Region (AuRA) (VISIMAT)
Restrictions on Maternity Ward Visits: Current Situation, Challenges and Recommendations in the AuRA Region
Maternal mental health in the postpartum period is a major public health issue in France. The 2021 National Perinatal Survey highlights high prevalence rates of mental health disorders among mothers, with 27.6% experiencing anxiety disorders, 16.7% experiencing depressive disorders and 5.4% having suicidal thoughts. Between 2016 and 2018, suicide was also the leading cause of maternal mortality in the year following childbirth, underscoring the severity and frequency of these disorders. In response, international guidelines, notably those of the World health Organisation (WHO), as well as national policies such as the 'First 1,000 Days' strategy, emphasise the importance of early, enhanced and individualised postnatal support. In France, this postpartum care tends to be structured around the Early Postnatal Interview and the recommended use of validated screening tools such as the Edinburgh Postnatal Depression Scale (EPDS).
However, the quality of postpartum care depends not only on screening and clinical follow-up, but also on organisational and environmental factors. Among these, the arrangements for maternity ward visits constitute a potential determinant of patients' experiences, likely to influence both their mental state, their rest, the establishment of breastfeeding and, indirectly, the health of the newborn. The exceptional measures implemented during the Covid-19 pandemic, notably the restriction of visits, have shown generally favourable effects, with improved satisfaction among patients and healthcare staff, better conditions for rest, facilitation of breastfeeding and a perceived improvement in working conditions.
However, these data were collected in an exceptional health context, which may introduce biases linked to the social, emotional and organisational constraints specific to this period. Their extrapolation to routine practice therefore remains uncertain. Furthermore, in the absence of specific national guidelines governing maternity ward visits, the current regulatory framework remains unclear and practices vary between institutions, often relying on local decisions that have not been scientifically evaluated.
Against this backdrop, the VISIMAT study aims to characterise maternity ward visiting arrangements outside of any exceptional circumstances and to assess their impact on the health of mothers and newborns, as well as on healthcare workers' working conditions. Its aim is to provide a scientific basis to inform the development of standardised recommendations and prevention messages.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Tipo de estudo
Inscrição (Estimado)
Estágio
- Não aplicável
Contactos e Locais
Contato de estudo
- Nome: Marion Beucher, PhD
- Número de telefone: +33 +33450637032
- E-mail: mbeucher@ch-annecygenevois.fr
Locais de estudo
-
-
Auvergne-Rhône-Alpes
-
Épagny, Auvergne-Rhône-Alpes, França, 74370
- CH Annecy Genevois
-
Contato:
- Marion Beucher, PhD
- Número de telefone: +33 +33450637032
- E-mail: mbeucher@ch-annecygenevois.fr
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
- Adulto
- Adulto mais velho
Aceita Voluntários Saudáveis
Descrição
Inclusion Criteria:
- Adult female patient (aged 18 or over),
- Female patient admitted to the maternity ward with her newborn baby or babies,
- Length of stay in the maternity ward of 48 hours or more,
- Female patient who has been informed about the study and has given her free, informed verbal consent to participate in the study.
Exclusion Criteria:
- Patients who have already participated in this study,
- Patients whose newborn(s) are hospitalised in neonatal units, neonatal intensive care units or neonatal resuscitation units,
- Patients who have given birth to three or more newborns (triplets or more),
- Patient whose newborn(s) has/have died,
- Patient unable to understand spoken or written French, making self-assessment impossible,
- Patient under guardianship, curatorship or placed under judicial protection,
- Patient not covered by the French social security system.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Outro
- Alocação: N / D
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Outro: Intervention (additionnal psychological assessment)
The only intervention prompted by the research involves referring patients with an EPDS score of ≥10 and/or a positive response to item 10 of the scale ('has already thought about harming themselves') to a psychologist.
|
The only intervention resulting from the research consists of referring patients with an EPDS score ≥ 10 and/or a positive response to item 10 of this scale ('has already thought about harming themselves') to a psychologist.
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Effect of visitor restriction levels implemented in maternity wards on mothers' postnatal depressive symptoms
Prazo: At discharge from hospitalization in the maternity ward, on average 48 hours
|
The incidence of depressive symptoms in the mother using the Edinburgh Postnatal Depression Scale (EPDS)
|
At discharge from hospitalization in the maternity ward, on average 48 hours
|
|
Effect of visitor restriction levels implemented in maternity wards on early indicators of newborn health.
Prazo: Until discharge from hospitalization in the maternity ward, on average 48 hours.
|
Neonatal weight change between birth and discharge from the maternity ward, reflecting the newborn's early health status.
|
Until discharge from hospitalization in the maternity ward, on average 48 hours.
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Noëllie FANTINATO, Midwife, Centre Hospitalier Annecy Genevois
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Outros números de identificação do estudo
- 24-08
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .